ACS Trial
The Phase 2 ACS Trial is enrolling up to 200 patients who suffered a heart attack within the previous 21 days. It is a randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the effect of VIA-2291 on vascular inflammation in patients after an acute coronary syndrome (ACS) event. Patients enrolled in the study will receive either a once-daily oral dose of VIA-2291 (25, 50 or 100mg) or placebo for three months. The ACS study has enrolled more than two-thirds of the targeted 200 patients for this trial and top-line data results are anticipated to be released shortly after the release of data from the CEA trial. This study is designed to establish dose and safety data in patients with acute coronary syndrome (ACS) who have experienced a recent heart attack, and includes measures of leukotrienes, biomarkers of inflammation as well as medical imaging of the coronary vessel wall to evaluate impact on plaque characteristics.